



September 2021

Harbour BioMed **Journal**
Investor Relations

02142.HK

HARBOUR
BIOMED



CONTENTS


HBM Overview	01
Company Announcement	02
Company News	03
2021 Interim Results	04
Hong Kong Biopharma Sector	05
Global Market Overview	06

HBM (02142.HK)

Overview	
Website – Investor Access	https://www.harbourbiomed.com/investor
Market Cap (08/31, MM HK\$)	5,591
Total Share Capital (MM)	768
Circulation Stock (MM)	768


In August, major indices of Hong Kong Exchange has been continuing to decline, following the trend of last month. The Hang Seng Index and the Hang Seng Composite Index dropped by 1.4% and 0.8% respectively. Moreover, healthcare sector plunged 9.0% along with the Hang Seng Healthcare Index by the end of August. HBM moved down with overall market trend.

HBM Holdings - Stock Performance (August)



* HBM share price increases since the first week of September

Hang Seng Healthcare Index (August)




Company Announcement

On August 31, the company receives Chinese regulatory approval of IND application to begin phase II clinical trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The IND approval is the fifth for HBM9161 in China. Batoclimab (HBM9161), a fully human anti-FcRn monoclonal antibodies, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases.

On August 30, the company releases 2021 Interim Results Announcement for the six months ended 30 June 2021. Corporate highlights as below:

- Critical milestones of core clinical assets have been achieved: Batoclimab HBM9161 proceeds into full clinical stage development across the first group of indications with positive trial results reported, preparations being made for the second group of indications. Phase III trial of Tanfanercept HBM9036 are advancing at full speed. Significant progress has been made in HBM4003's global development plan, and data readout of the clinical trial results will be released at ESMO (the European Society of Medical Oncology) in September 2021.
- Multiple research programs are developing at an accelerated pace, including: HBM7008, HBM9378, HBM1022, HBM1020, HBM7020, HBM7015, HBM1029 and HBM1007.
- Scientific team has put forth a strong R&D contribution: within reporting period, the Company has applied for 28 patents with 4 patents issued including 1US and 3HK applications, while presenting research results at multiple medical and academic conferences.
- Strengthened global partnerships continuously unlock value of HBM's integrated antibody discovery platforms through entering into research cooperation agreement with the Dana-Farber Cancer Institute, Affiliated Hospital of Harvard Medical School; reaching a strategic collaboration agreement with BioMap, an AI driven research and development platform focusing on precision medicine; and further advancing academic cooperation with the Icahn School of Medicine at Mount Sinai.

On August 18, the board of directors of HBM of Holdings Limited announces that a meeting of the Board of the Company will be held on Monday, 30 August 2021 for the purpose of considering and approving the interim results of the Group for the six months ended 30 June 2021.



Company News

01

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

02

Harbour BioMed Reports 2021 Interim Results: Product Development Breakthroughs Continue to Unlock Value of Integrated Antibody Discovery Platform





03


Harbour BioMed collaborates with the Shanghai Tech University to build up biomedical practice platform

04

Frontiers in Immunology: No ideal therapeutics for NMOSED

2021 Interim Results

 Clinical Pipelines	<ul style="list-style-type: none"> ➤ 3 BLA in 2022 ➤ 2 near-term commercialization assets ➤ 7 ongoing clinical trials: 3 indications in HBM9161, HBM9036, HBM4003 with 1 mono therapy & 2 combination therapy
 Pre-clinical Assets	<ul style="list-style-type: none"> ➤ 3 bispecific antibody: HBM7008(B7H4X4-1BB)、HBM7020(BCMAXCD3)、HBM7015(PD-L1XTGF-β) ➤ 5 monoclonal antibody: HBM9378(TSLP)、HBM1020(B7H7)、HBM1022(CCR8)、HBM1007(CD73)、HBM1029(Claudin18.2) ➤ 7 IND in 2021/2022
 Global Collaboration	<ul style="list-style-type: none"> ➤ Dana-Farber (Affiliated Hospital of Harvard Medical School): working together to develop novel therapeutics ➤ Mount Sinai: further developing collaboration to achieve benefits together ➤ BioMap: reaching a strategic collaboration focusing on research, development and transformation of new antibody
 Financial Highlights	<ul style="list-style-type: none"> ➤ R&D costs: US\$41.2 million (June 30, 2021) ➤ Cash and bank balances: US\$281 million (June 30, 2021)




Hong Kong Biopharma Sector

Market Overview

Compared to last month, in August 2021, the Hang Seng Composite Index (HSCI) closed at 4,024.55, down 0.8%. The Hang Seng Healthcare Index (HSHCI) closed at 6,189.86.79, down 9.0%. And the China Hong Kong Biotech index (CESHKB.CSI) closed at 12,835.23, down 8.4%.

HK Listing Biopharma Companies (18A)



Global Market Overview

Global Market Index			
	Closing Price		
	2021.08.02	2021.08.13	2021.08.31
Dow Jones Industrial	34,838.16	35,515.38	35,360.73
Nasdaq Composite	14,681.07	14,822.90	15,259.24
UK FTSE 100	7,081.72	7,218.71	7,119.70
German DAX	15,568.73	15,977.44	15,835.09
France CAC40	6,675.90	6,896.04	6,680.18

HK Market Index			
	Closing Price		
	2021.08.02	2021.08.13	2021.08.31
Hang Seng Index	26,235.8	26,391.62	25,878.99
Hang Seng Composite Index	4,055.48	4,063.32	4,024.55
Hang Seng Tech Index	6,796.25	6,589.54	6,607.78
HS China Enterprise Index	9,336.6	9,377.79	9,183.76
Hang Seng Healthcare Index	6,802.69	6,575.18	6,189.86

Major Global Economic Indicators – August			
Country	Related Indicator	Estimated	Actual
US	Number of Unemployment Benefits Initial Claiming for the week of 8/7 (thousand people)	20	37.5
US	The Index of Consumer Sentiment of the University of Michigan	123.9	70.2
Eurozone	Sentix Investor Confidence Index	21	22.2
Germany	ZEW Economic Sentiment Index	118.5	40.4
Germany	Gfk Consumer Confidence Barometer	102.1	-0.3

- The ZEW Economic Sentiment Index for the Euro Zone in August fell to 42.7 from last time announced
- US API crude oil inventories (10,000 barrels) were higher than expected at -816k barrels as the week of August 6
- US EIA natural gas inventories (100 million cubic feet) reached the expected 49 billion cubic feet as the week of August 6

HARBOUR BIOMED



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE™) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

ir@harbourbiomed.com
www.harbourbiomed.com

linkedin:
<https://www.linkedin.com/company/13244036/admin/>